Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.

e20012Background: Pomalidomide (POM) is a third–generation immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) patients (pts) previously treated with bortezomib and lenalidomide (LEN). POM in combination with dexamethasone has been shown to overcome resistance and to be effective not only in RRMM pts but also in high risk myeloma cases. In this trial, we are evaluating the efficacy, safety and tolerability of POM replacing LEN for pts who were refractory to a LEN and steroid-containing regimen. Methods: This is a multicenter, open-label and non-randomized study. Pts who have failed a combination regimen containing LEN were treated with POM along with all of the other drugs previously used in the regimen. POM administered orally (dose is determined based on the previous regimen) on days 1-21 of a 28-day cycle, whereas other drugs are administered using the same schedule(s), dose(s) and drug combination as the last LEN-containing regimen. The...